alpibectir   Click here for help

GtoPdb Ligand ID: 12957

Synonyms: BVL-GSK098
Compound class: Synthetic organic
Comment: Alpibectir is being developed by BioVersys AG and GlaxoSmithKline as an oral treatment for tuberculosis (TB) in combination with ethionamide or prothionamide. Alpibectir targets bacterial transcriptional regulators and potentiates the activity of drugs used in the treatment of TB, in particular drugs that are activatable via the EthA pathway. It is one of the spiroisoxazoline class of compounds claimed in patent WO2019034700A1 [1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 5
Topological polar surface area 41.9
Molecular weight 332.24
XLogP 3.13
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C(CC(F)(F)F)C(=O)N1CCC2(CC1)CC(=NO2)C(F)(F)F
Isomeric SMILES C1CN(CCC12CC(=NO2)C(F)(F)F)C(=O)CCC(F)(F)F
InChI InChI=1S/C12H14F6N2O2/c13-11(14,15)2-1-9(21)20-5-3-10(4-6-20)7-8(19-22-10)12(16,17)18/h1-7H2
InChI Key ZEAVKHMQTZBUND-UHFFFAOYSA-N
References
1. De Francisco EP, Remuinan-Blanco MJ, Bourotte M, Deprez B , Willand N. (2019)
Novel compounds.
Patent number: WO2019034700A1. Assignee: GlaxoSmithKline, BioVersys. Priority date: 15/08/2018. Publication date: 21/02/2019.
2. Maitre T, Baulard A, Aubry A, Veziris N. (2024)
Optimizing the use of current antituberculosis drugs to overcome drug resistance in Mycobacterium tuberculosis.
Infect Dis Now, 54 (1): 104807. [PMID:37839674]